Interpharm(OTC) IPAH

Interpharm Holdings, Inc. specializes in the formulation, manufacturing, and commercialization of generic pharmaceuticals. Established in 1984, the company operates primarily from Hauppauge, New York, supplying a diverse range of clients including retail chains and healthcare organizations.

Products and Services

• Generic pharmaceuticals, including prescription and over-the-counter medications
• Formulation and manufacturing services tailored to client specifications
• Distribution partnerships with major retail and wholesale networks

Growth Outlook

• Continued expansion in the generic pharmaceuticals market is anticipated
• Strategic partnerships with healthcare organizations may enhance market reach
• Investment in R&D could lead to innovative product offerings

Financial Highlights

• Recent quarterly revenue of $16.2 million reflects a strong market presence
• Trailing twelve months (TTM) gross profit margin stands at 28.66%
• Current ratio of 1.05 indicates adequate short-term financial health

Interpharm Holdings, Inc. has established itself as a key player in the generic pharmaceuticals sector, focusing on both prescription and over-the-counter products. The company's ability to cater to a wide array of clients, including significant retail chains and managed healthcare organizations, positions it well for future growth. The growth outlook remains positive, driven by anticipated market expansion and strategic partnerships that may enhance distribution capabilities. Additionally, ongoing investment in research and development could lead to innovative products, further solidifying the company's competitive edge. Financially, the company has demonstrated resilience with a recent quarterly revenue of $16.2 million, showcasing its operational effectiveness. The gross profit margin of 28.66% indicates a solid profitability framework, while a current ratio of 1.05 suggests that the company is well-positioned to meet its short-term obligations. Overall, Interpharm Holdings, Inc. presents a compelling opportunity for investors interested in the pharmaceutical sector.